Fussen

This research aims to evaluate participant satisfaction with subcutaneous SC administration of ocrelizumab in people with multiple sclerosis MS. Participants include those diagnosed with relapsing-remitting MS RMS or primary progressive MS PPMS according to the 2017 McDonald criteria. The study focuses on assessing satisfaction after 12 months of treatment using the Therapy Administration Satisfaction Questionnaire subcutaneous TASQ-SC. Participants will receive ocrelizumab as a subcutaneous injection for the first time as part of their routine MS therapy, following their physicians judgment and local guidelines. The study observes treatment satisfaction over a 12-month period without altering standard care. Treatment administration is monitored in accordance with usual clinical practice. Throughout the study, participants will complete satisfaction questionnaires at baseline, 6 months, and 12 months. Researchers will also measure neurofilament light chain NfL protein levels in serum at these timepoints and analyze their correlations with MS relapse, disability scale scores, previous treatments, and other factors. Safety is monitored by recording adverse events up to 12 months. The study involves regular assessments to understand the effects of ocrelizumab SC on patient satisfaction and biological markers over one year.

Researchers are evaluating the effects of cold water hydrotherapy on patients with Post-COVID Syndrome, a condition where symptoms like fatigue, autonomic imbalance, and inflammation persist after COVID-19 infection. The study aims to compare quality of life improvements between those receiving hydrotherapy and those receiving usual care without it. The trial is a randomized controlled study sponsored by Eggensberger OHG. Participants in the experimental group will undergo cold water hydrotherapy sessions lasting 5 to 10 minutes, four times daily during a 3-week program, followed by once daily sessions during a 6-month follow-up. The hydrotherapy involves tailored techniques such as washing and pouring. The control group will receive usual care at home without hydrotherapy. Standard medical care is also provided during the 3-week stay for the treatment group. Participants will provide demographic and health data at baseline, including symptoms, smoking history, and prior COVID-19 illness severity. They will undergo autonomic function testing and report work ability and sick leave days. Researchers will monitor quality of life, fatigue, sleep quality, autonomic function, blood pressure, adherence to hydrotherapy, and adverse events over the 6-month period. Daily well-being and post-exertional malaise will also be documented to assess long-term effects.